Regulatory milestones

Biogen Idec Inc. (NASDAQ:BIIB) gained $4.40 to $176.78 last week after submitting a BLA to FDA for rFVIIIFc to treat hemophilia A. The product is partnered with Swedish Orphan Biovitrum AB (SSE:SOBI), which gained SEK4.10 (11%) to SEK42 last week.